The identification of oncogenic alterations in subsets of non-small cell lung cancers (NSCLC) is transforming clinical care. Genomic rearrangements in the anaplastic lymphoma kinase (ALK) are detected in 3 to 7% of NSCLC patients. The ALK tyrosine kinase inhibitor crizotinib has demonstrated clinical efficacy in ALK rearranged NSCLC patients and was recently approved by the FDA. Crizotinib is currently under additional phase III clinical development as both initial and second line therapy for advanced ALK rearranged NSCLC. However new challenges in the diagnosis and treatment of this subset of NSCLC have emerged. These include the most effective means of diagnosing ALK rearranged NSCLC and the emergence of acquired drug resistance to crizotinib. In this review we will review current treatment and diagnosis as well as the present knowledge on acquired resistance mechanisms to crizotinib and discuss the strategies presently underway to clinically overcome acquired drug resistance.
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Background
The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase initially identified as a result of a translocation in anaplastic large cell lymphoma (ALCL) in 1998 (1) . ALK plays a role during development and is not expressed in most, if any, adult tissues. In 2007, a fusion of ALK with echinoderm microtubule-associated protein-like 4 (EML4) was first identified in a non-small cell lung cancer (NSCLC) patient (2) . This occurs due to a chromosomal inversion on chromosome 2p resulting in the formation of the EML4-ALK fusion oncogene (2) . The chromosomal inversion does not always occur in the exact same location and multiple EML4-ALK variants have been identified (3) . All involve the intracellular tyrosine kinase domain of ALK beginning at the portion encoded by exon 20. EML4, however, is variably truncated and gives rise to various variants of EML4-ALK (3) . The most common variants were E13;A20 (the nomenclature refers to the exons in EML4 (E) that are fused to ALK (A)) and E6a/b;A20, which are also referred to as variants 1 and 3a/b, respectively. In addition to at least 9 variants have been reported to date, rare non-EML4 fusions partners have also been described (herein collectively referred to as ALK rearranged NSCLC) (3) .
The EML4-ALK fusion protein is oncogenic both in vitro and in vivo (2, 4, 5) .
EML4-ALK fusions result in protein dimerization and constitutive activation of ALK
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Author Manuscript Published OnlineFirst on October 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 Detection of the ALK rearrangements can be challenging and several methods are currently being evaluated including fluorescence in situ hybridization (FISH), reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC). Each technique is associated with specific strengths and weaknesses for the screening of samples for ALK rearrangements.
Given the recent FDA approval of critozinib the evaluation for an ALK rearrangement should take place early on the in the treatment course. Routine molecular diagnostics need to include evaluation for both epidermal growth factor receptor (EGFR) mutations and for ALK rearrangements as the therapies are different for these two genetically defined subsets of lung cancer.
FISH
Current clinical trials of the ALK kinase inhibitor crizotinib use FISH as the diagnostic test for detecting an ALK rearrangement. This test is also recently FDA approved. In this assay, the 5' and 3' ends of the ALK gene are differently labeled with red and green fluorescent probes. Under normal circumstances, the two probes are close together.
However, in the presence of an ALK rearrangement they are further apart (hence the term "break-apart" probe) red and green signals (8) October 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 specificity have been reported (10) (11) (12) . This assay detects ALK rearrangements regardless of the ALK fusion partner or the specific EML4-ALK variant. However, as EML4-ALK results from a chromosomal inversion on chromosome 2p and because the two genes are normally only about 12 Mb apart, the split signal can sometimes be very subtle and challenging to detect. In addition, as the assay requires specialized technical resources and expertise, it is not available in all pathology laboratories. Furthermore, FISH is a relatively low throughput assay and costly which is not ideal for detecting a relatively infrequent subset of NSCLC patients. Recent studies have compared ALK chromogenic in situ hybridization (CISH) to FISH and have demonstrated > 95% agreement between the two methods (13) . CISH has potential advantages over FISH as it can be performed without the need for a fluorescence microscope and the signals are stable over long periods of time.
RT-PCR
As an alternative method of screening and confirming an ALK rearrangement, RT-PCR can also be used and offers some unique advantages. In the absence of contamination, this assay is very specific and the resulting PCR product can be sequenced to help define the specific type of translocation present (14) . It is the only technique capable of definitively defining both the ALK fusion partner and the precise fusion variant. This Author Manuscript Published OnlineFirst on October 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 technique can also be applied to samples with limited tissue, for example sputum specimens or material obtained by bronchoscopic biopsies (15) . While RT-PCR is potentially the most sensitive assay, it requires adequate and sufficient quality RNA, which can be difficult to obtain from routine clinical samples such as formalin fixed paraffin embedded (FFPE) tumor specimens. In addition, given the large number of potential EML4-ALK variants, and non-EML4 ALK fusions, several PCR primer sets are necessary to cover all of the potential ALK rearrangements.
IHC
Immunohistochemistry is a diagnostic tool available in every clinical pathology laboratory. In addition, IHC is cost effective, can be incorporated into the existing sample flow for pathologists and an ideal tool to screen for a subpopulation of patients such as those harboring ALK rearrangements. Furthermore, as ALK is not normally expressed in the lung or in adults, any degree of ALK expression may be a sign of aberrant ALK expression due to an ALK rearrangement. The initial attempts to use ALK antibodies, used in to diagnose ALCL, in NSCLC were disappointing as in lung cancer ALK expression is much lower than in ALCL harboring an ALK translocation (9, 16) .
However, since the initial efforts, the detection of ALK by IHC has improved due to incorporation of techniques to enhance the IHC signal and to the development of more Author Manuscript Published OnlineFirst on October 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 sensitive ALK antibodies (9, 16) . Methods to amplify the IHC signaling using existing antibodies include the intercalated antibody-enhanced polymer (iAEP) approach (used with the ALK antibody 5A4) and tyramide amplification (using the ALK antibody ALK1) (9, 16) . For example, the tyramide amplification method improves the ability to detect ALK by IHC from 40% to 80% of specimens harboring ALK rearrangements defined by FISH (9) . Both techniques have been used successfully as a screening method in surgically resected specimens, as well as in smaller samples obtained by transbronchial needle biopsies (17) . The mouse monoclonal antibody (D5F3) for ALK appears to offer sufficient sensitivity (100%) and specificity (99%), as compared with ALK FISH, and maybe able to be developed into a clinical diagnostic tool (11) .
However this is not yet commercially available thus limiting the ability to use it as a screening test. It is anticipated that the optimization of both IHC methods and identification of novel ALK antibodies will continue to evolve. IHC holds the greatest hope for a widely available, cost effective and rapid screening tool for the identification of patients with ALK rearranged NSCLC.
Treatment of ALK rearranged NSCLC
Since the ALK tyrosine kinase activity is necessary for its transforming activity Author Manuscript Published OnlineFirst on October 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 and oncogenicity, its inhibition by a kinase inhibitor represents a potential therapeutic approach for ALK rearranged NSCLC (Fig 1B) . Several ALK inhibitors have been identified and are being evaluated in pre-clinical models both in vitro and in vivo as potential clinical therapies (4, (18) (19) (20) . In such models, ALK inhibitors lead to apoptosis in vitro and to tumor shrinkage in vivo thus demonstrating the phenomenon of "oncogene addiction" (4, 5, 18, 21) (Fig 1B) . This is further highlighted by the dramatic clinical studies to date. Crizotinib (PF-02341066), an oral kinase inhibitor initially designed as a MET inhibitor, is a clinically effective ALK inhibitor in NSCLC patients harboring ALK rearrangements (10) . In the phase I clinical trial, the response rate to crizotinib was 57% in the 82 treated patients (10) . The study also highlighted the screening necessary to identify the patients. Over 1500 patients needed to be screened to identify the 82 patients with ALK rearrangements (10) . As our targeted therapies are increasingly focusing on subsets of cancer patients the screening programs necessary to identify such patients also need to evolve. The ALK example highlights the value of this approach both for drug development and as means of identifying patients that will derive the greatest benefit from crizotinib treatment. Based on the dramatic clinical activity crizotinib has recently been approved by the FDA for ALK rearranged NSCLC.
The clinical development has occurred over a remarkably short period of time, from the 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 initial Author Manuscript Published OnlineFirst on October 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 development of acquired drug resistance (23) . The mechanistic understanding of drug resistance may help in the development effective subsequent clinical treatments and/or rational combination therapeutic strategies (Figure 2 ). How to best treat patients that develop acquired resistance to crizotinib has not yet been defined. However, several recent studies have begun to identify and study crizotinib resistance mechanisms. These include secondary mutations in the target of the kinase itself which abrogate the inhibitory activity of the drug and activation of alternative signaling pathways that bypass the continued requirement for inhibition of the original target (Fig 1C and D) (19, (24) (25) (26) . The fraction of crizotinib resistance that is mediated by a secondary mutation as compared to activation by an alternative signaling pathway is currently not known.
Secondary mutations in kinases are a common mechanism of acquired drug resistance to kinase inhibitors (27) . To date four acquired drug resistance mutations, all identified from crizotinib treated NSCLC or inflammatory myofibroblastic tumor (IMT) patients, have been reported (Fig 1C) (24-26) . These mutations either involve the "gatekeeper" residue (L1196M) or residues away from crizotinib binding (L1152R, Author Manuscript Published OnlineFirst on October 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 L1196M mutation), promotion of a conformational change disfavoring critozinib binding and by increasing the affinity for ATP (24). Structural and biochemical studies of each of these mutations will be necessary to further understand how they lead to crizotinib resistance. In addition such studies may provide insight into the potential efficacy of next generation ALK kinase inhibitors.
Data is also emerging on mechanisms of crizotinib resistance that result from activation of an alternative signaling pathway. A recent study reported that activation of the EGFR signaling pathway can bypass the continued requirement for inhibition of ALK contributes to ALK inhibitor resistance (26) . In some of these models, EGFR is activated by a ligand mediated process (Fig 1D) . Concurrent inhibition of both EGFR and ALK is therapeutically effective in such resistant models (26) . Additional studies are needed to evaluate changes in EGFR signaling from crizotinib treated tumor specimens and also to determine whether activation of other receptor tyrosine kinases can also contribute to crizotinib resistance.
Understanding the specific mechanism(s) of drug resistance is critical in selecting and evaluating subsequent therapeutic approaches. It is imperative that any new therapeutic strategy for patients that have developed acquired resistance to crizotinib incorporate tumor biopsies as part of the early clinical trials. This will be the only way Author Manuscript Published OnlineFirst on October 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 to understand the potential benefits and limitations of a new therapeutic approach.
Treatment of ALK rearranged tumors with HSP90 Inhibitors
A second class of agents that has demonstrated clinical efficacy in ALK rearranged NSCLC patients is heat shock protein 90 (HSP90) inhibitors. EML4-ALK associates in complex with multiple cellular chaperones including HSP90 (5) . Inhibitors of HSP90 disrupt this complex, lead to degradation of EML4-ALK and to tumor regression in xenograft and genetically engineered models of EML4-ALK NSCLC (5) . In addition, cell lines bearing the crizotinib resistance mutations (L1196M and F1174L) remain equally sensitive to HSP90 inhibitors compared to ones without the secondary mutations (19, 25) .
Clinical studies of two HSP90 inhibitors, retaspimycin (IPI-504) and ganetespib (STA-9090) have also demonstrated efficacy in ALK NSCLC patients (28, 29) . Neither study was specifically designed to evaluate ALK rearranged patients and included NSCLC patients with other genotypes (such as EGFR and KRAS mutant). However, a substantial proportion of the ALK rearranged patients had partial responses which was not observed in patients with other genotypes (28, 29) . Why EML4-ALK is a particularly good HSP90 client protein clinically remains to be determined. NSCLC. Of note, the studies to date have predominately treated crizotinib naïve patients and whether HSP90 inhibitors will also be clinically effective in patients that have developed acquired resistance to crtizotinib is not presently known.
Next generation ALK kinase inhibitors and novel therapeutic combinations
Several new ALK kinase inhibitors have been developed and are currently entering early clinical development ( Table 1) . Some of these agents, including CH5424802, AP26113 and X-396, have been tested, and have been demonstrated pre-clinical efficacy, in models bearing crizotinib resistance mutations (18) (19) (20) . Many of these new ALK inhibitors are also more potent inhibitors of ALK than crizotinib which was originally identified as a MET inhibitor (18, 20) . Whether this increase in potency will translate into an increase in clinical efficacy is can only be determined from future clinical trials.
Two drug development strategies are likely going to be employed. These include treating patients that have developed acquired resistance to crizotinib and patients that are crizotinib naïve. The former approach assumes that clinical acquired resistance to crizotinib will be mediated by an ALK dependent process (e.g. secondary mutation).
However, the studies so far from actual patients that have developed acquired crizotinib resistance, to define the fraction of crizotinib resistance that is mediated by secondary mutations, are limited. Author Manuscript Published OnlineFirst on October 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 Figure Legends Author Manuscript Published OnlineFirst on October 18, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1404 
